Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is ...
Shares of Cencora Inc. COR slid 2.56% to $254.00 Wednesday, on what proved to be an all-around mixed trading session for the ...
2d
Barchart on MSNIs Cencora Stock Outperforming the Nasdaq?With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions ...
We recently published a list of 10 Stocks With At Least $30 Million In Insider Sales Recently. In this article, we are going ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora (NYSE:COR) has made headlines with its announcement on March 10, 2025, detailing plans for strategic acquisitions and investments in technology infrastructure, aiming to drive future growth.
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. Learn more on COR stock here.
AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...
With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions provider specializing in pharmaceutical distribution and related services.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results